Skip to content

Multidisciplinary Program Optimization of Drug Prescription : Impact on the Quality of Drug Prescription in Hospitalized Elderly Patients

OPMED STUDY: Multidisciplinary Program Optimization of Drug Prescription : Impact on the Quality of Drug Prescription in Hospitalized Elderly Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01947270
Acronym
OPMED
Enrollment
3055
Registered
2013-09-20
Start date
2013-01-31
Completion date
2017-06-30
Last updated
2017-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Potentially Inappropriate Medications

Keywords

Potentially inappropriate medications, Elderly, Prevention, Multidisciplinary program, Checklist, Stepped wedge design, AGED, 75 AND OVER

Brief summary

Drug prescription is a fundamental component of care for the elderly. Even if drugs are a chance for the older patient, because of changes in pharmacological, pharmacokinetic and pharmacodynamic parameters related with age and acute/or chronic pathologies, the risks associated with drug prescription, particularly those associated with potentially inappropriate medication (PIM), are increased in the elderly. We suppose that many of hospitalized elderly have at least one prescribed medication without valid indication. Conversely, many diseases are currently undertreated in elderly patients: e.g. medicines used to treat heart failure and osteoporosis are underused in 20 to 70% of patients. Moreover, PMI prescription is associated with an increased of morbidity, mortality, risk of drug-related adverse events, utilization of health care system, care costs and impairment of quality of life. Thus, optimization of drug prescription is a major concern for improvement of the quality and safety of care in elderly. The investigators' hypothesis is that a multidisciplinary program entitled Optimisation de la Prescription MEDicamenteuse (Optimization of drug prescribing) focused on drug prescription optimization including a physician training to the specificity of the drug prescription in the elderly and a checklist allowing an adapted and standardized pharmaceutical analysis is effective in reducing PIM in elderly patients hospitalized in short-term medical and geriatric care departments.

Interventions

OTHER Optimisation de la Prescription MEDicamenteuse (Optimization of drug prescribing)

The multidisciplinary intervention program include: * Awareness and training of doctors by two experts (a geriatrician and a pharmacist) within participating departments. * Implementation of a checklist which aims to conduct an adapted and standardized pharmaceutical analysis

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
75 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female subject aged over 75 years hospitalized in one of the participating department * Patient agreed to participate

Exclusion criteria

* Patient with a predictive length of stay equal or less than 48 hours * Patients admitted in terminal illness

Design outcomes

Primary

MeasureTime frameDescription
Proportion of potentially inappropriate medications (PIM) prescribed in discharge of hospitalized patients from 75 years old.at discharge (average 3 weeks)Proportion of prescribed PIM will be expressed as the ratio of PIM to the total number of medication in discharge prescription sheet. PIM will be identified by 2 experts (1 doctor and 1 pharmacist) based on criteria from the lists STOPP/START and Laroche.

Secondary

MeasureTime frame
Total number of drugs prescribed per discharge prescription sheetat discharge (average 3 weeks)
Number of rehospitalization within 12 months following discharge12 months after inclusion
Number of emergency admission within 12 months following hospitalization12 months after inclusion
Mortality within 12 months after hospitalization12 months after inclusion

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026